Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
Precision Prevention: Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
PRIMARY OBJECTIVES:
I. To assess patient interest and emotional responses toward EERA and return of results.
II. To assess provider attitudes toward EERA integration into clinical workflows.
OUTLINE: This is an observational study. Participants are assigned to 1 of 3 aims.
AIM I: Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' and patients' medical records are reviewed.
AIM II: COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
AIM III: Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week. Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' medical records are reviewed.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope Medical Center
-
主任研究者:
- Stacy W. Gray
-
コンタクト:
- Stacy W. Gray
- 電話番号:626-218-4768
- メール:stagray@coh.org
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
AIM 1 INCLUSION CRITERIA:
ONE of the following:
- Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no Pathogenic/Likely Pathogenic [P/LP] in breast cancer related genes) OR high risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model or gene mutation carrier, P/LP carrier in breast cancer related genes including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53) OR early onset breast cancer (defined by a breast cancer diagnosis in a patient younger than 50 years of age)
- Age: ≥ 18 years
- Speak English or Spanish
- Sex: female
Willingness to:
- Participate in study activities
- Permit medical record/ clinical laboratory result review
AIM 2 INCLUSION CRITERIA
- Practice at COH (i.e., genetic counselors, geneticists, oncologists, nurse practitioners)
Willingness to:
- Participate in study activities
AIM 3 INCLUSION CRITERIA:
- Provide written consent
ONE of the following:
- Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no P/LP in breast cancer related genes) OR High risk: empirical risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model and no P/LP in breast cancer related genes) OR High Risk: gene carrier (defined by P/LP carrier in breast cancer related genes, including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53)
- Age: ≥ 18 years
- Speak English or Spanish
- Sex: female
Willingness to:
- Wear the wristband for 1 week
- Participate in study activities
- Permit medical record/ clinical laboratory result review
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Observational Aim I
Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
Participants' and patients' medical records are reviewed.
|
非介入研究
他の名前:
|
|
Observational Aim II
COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
|
非介入研究
他の名前:
|
|
Observational Aim III
Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week.
Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes.
Participants' medical records are reviewed.
|
非介入研究
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient survey responses on perceived utility
時間枠:Up to one year
|
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using analysis of covariance (ANCOVA).
Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores.
ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors.
Interview sessions will be audio-recorded and transcribed verbatim.
|
Up to one year
|
|
Patient survey responses on willingness to engage
時間枠:Up to one year
|
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA.
Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores.
ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors.
Interview sessions will be audio-recorded and transcribed verbatim.
|
Up to one year
|
|
Patient survey responses on preferences for receiving EERA results
時間枠:Up to one year
|
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA.
Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores.
ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors.
Interview sessions will be audio-recorded and transcribed verbatim.
|
Up to one year
|
|
Provider survey responses on perceived utility
時間枠:Up to one year
|
Descriptive analysis will be used to examine all quantitative variables.
|
Up to one year
|
|
Provider survey responses on feasibility
時間枠:Up to one year
|
Descriptive analysis will be used to examine all quantitative variables.
|
Up to one year
|
|
Provider survey responses on preferences for EERA disclosures into workflows
時間枠:Up to one year
|
Descriptive analysis will be used to examine all quantitative variables.
|
Up to one year
|
|
Proportion of participants who wear the work wristband for a total of 1 week
時間枠:Up to one year
|
Feasibility will be defined as the proportion of participants who wear the work wristband for a total of 1 week.
The feasibility rate will be summarized descriptively using point estimates and 95% confidence intervals.
|
Up to one year
|
|
Chemical exposure measured by Fresh Air Clip wristband
時間枠:Up to one year
|
Acceptability will be measured in the follow-up survey using the question: "Overall, how acceptable did you find wearing the 'Fresh Air clip' wristband to measure chemical exposures in your daily life?"
Participants who respond "No opinion," "Acceptable," or "Completely acceptable" will be categorized as finding the wristband acceptable.
The acceptability rate will be summarized descriptively using point estimates and 95% confidence intervals.
|
Up to one year
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Stacy W Gray、City of Hope Medical Center
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 260159 (その他の識別子:City of Hope Medical Center)
- P30CA033572 (米国 NIH グラント/契約)
- NCI-2026-04271 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。